Expedited Early Phase
With over 50% of PM’s and over 60% of CRA’s at Pharm-Olam experienced in early phase oncology trials including complex adaptive designs and FIH trials, and with a specialization in early phase hematology-oncology research, including leukemia, lymphoma, and myeloma, we are ideally positioned to expedite your next Phase I-II trial.
Pharm-Olam’s immuno-oncology (I-O) experience spans a variety of novel therapy types including monoclonal antibodies, immune checkpoint inhibitors, cell and gene therapies, GMO, cytokines, and cancer vaccines. As advancements in I-O therapies continues faster than ever Pharm-Olam looks to drive this area of research forward and bring these complex treatments to the patients in need.
Advantageous Site & Vendor Relationships
Pharm-Olam has an established site network with leading oncology sites as well as advantageous vendor relationships and optimized processes for specialty labs (biomarkers, tumor biopsy, pharmacokinetics [PK] etc.) and central reading (ECG, images) which augment the full service offering from Pharm-Olam to provide a near seamless trial experience.
Our deep expertise in hematology encompasses liquid tumors, autoimmune hematological diseases, and hematological rare diseases. Having supported trials in idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and rare conditions such as myelofibrosis, we recognize the complexities of this research and offer the solutions and expertise needed to deliver on time, at the highest possible quality.